Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Shanghai Pudong Hospital
- Target Recruit Count
- 204
- Registration Number
- NCT05656079
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Shanghai, China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Target Recruit Count
- 20
- Registration Number
- NCT05491694
TACE With Dicycloplatin(TP21) in Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Gao-jun Teng
- Target Recruit Count
- 332
- Registration Number
- NCT05472896
- Locations
- 🇨🇳
Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05447702
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study for the Adjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 2413
- Registration Number
- NCT05420467
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study for the Neoadjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 1576
- Registration Number
- NCT05420454
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT05287308
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Neoadjuvant Treatment of Breast Cancer
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT05121350
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.